<DOC>
	<DOCNO>NCT01732445</DOCNO>
	<brief_summary>This phase II pilot trial study well ruxolitinib phosphate danazol work treat anemia patient myelofibrosis . Ruxolitinib phosphate danazol may cause body make red blood cell . They use treat anemia patient myelofibrosis .</brief_summary>
	<brief_title>Ruxolitinib Phosphate Danazol Treating Anemia Patients With Myelofibrosis</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate efficacy ( best overall response ) ruxolitinib ( ruxolitinib phosphate ) danazol patient myelofibrosis suffer anemia . SECONDARY OBJECTIVES : I . To evaluate overall survival patient myelofibrosis suffer anemia initiate ruxolitinib danazol . II . To evaluate adverse event profile ruxolitinib danazol patient myelofibrosis suffer anemia . TERTIARY OBJECTIVES : I . To evaluate quality life ( QOL ) patient-reported symptom use Myeloproliferative Neoplasm Symptom Assessment Form ( MPN-SAF ) European Organization Research Treatment Cancer ( EORTC ) Quality Life Questionnaire-Core 30 ( QLQ-C30 ) ruxolitinib danazol patient myelofibrosis suffer anemia . OUTLINE : Patients receive ruxolitinib phosphate orally ( PO ) twice daily ( BID ) danazol PO thrice daily ( TID ) day 1-56 . Treatment repeat every 56 day 6 course absence disease progression unacceptable toxicity . At treat physician 's discretion , patient may continue treatment past 6 course without disease progression . After completion study treatment , patient follow every 6 month 2 year .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Danazol</mesh_term>
	<criteria>Histological confirmation primary myelofibrosis ( MF ) , post polycythemia vera ( PV ) post essential thrombocythemia ( ET ) myelofibrosis ( intermediate 1 , intermediate II high risk ) require medical therapy Anemia require trial entry ( define hemoglobin &lt; 10g/dL transfusion dependent [ need transfusion anytime past 6 month ] ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 study entry Absolute neutrophil count ( ANC ) &gt; = 1000/uL Platelet count &gt; = 50,000/uL Serum creatinine = &lt; 1.5 x upper limit normal ( ULN ) Total bilirubin = &lt; 1.5 x ULN ; total bilirubin &gt; 1.5 x ULN , direct bilirubin perform must &lt; 1.5mg/dL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 3 x ULN ; high value ( i.e. , = &lt; 5 x ULN ) allow clinically compatible hepatic extramedullary hematopoiesis Life expectancy &gt; = 6 month Patient able provide voluntary write informed consent participate Willing comply schedule visit , treatment plan , laboratory assessment , studyrelated procedure Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Any chemotherapy ( e.g. , hydroxyurea ) , immunomodulatory drug therapy ( e.g. , thalidomide , interferonalpha ) , immunosuppressive therapy , corticosteroid &gt; 10 mg/day prednisone equivalent , growth factor treatment ( e.g. , erythropoietin ) , hormone ( e.g. , androgen , danazol ) = &lt; 14 day prior registration ; note : patient ruxolitinib may continue without 14 day wash treat physician 's discretion Major surgery = &lt; 28 day radiation = &lt; 6 month prior registration Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Active acute infection require antibiotic Uncontrolled congestive heart failure ( New York Heart Association classification 3 4 ) , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass , graft surgery , transient ischemic attack , pulmonary embolism within 3 month prior registration Participation study investigational agent ( drug , biologic , device ) = &lt; 30 day , unless nontreatment phase Any following : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Known human immunodeficiency virus acquire immunodeficiency syndromerelated illness Clinically active hepatitis B C Active malignancy MF , except adequately treat basal cell carcinoma squamous cell carcinoma skin , cervical carcinoma situ malignancy stable therapy 5 year Patient currently take simvastatin , lovastatin dose great 10 mg/day Men prostate specific antigen ( PSA ) &gt; 4 ng/ml uncontrolled benign prostatic hypertrophy Patient receive prior combination treatment ruxolitinib danazol together ; note : previous treatment ruxolitinib and/or danazol single agent therapy allow Receiving medication substance strong moderate inhibitor cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) ; use follow strong moderate inhibitor prohibit = &lt; 7 day prior registration Strong inhibitor CYP3A4 : Indinavir ( Crixivan ) Nelfinavir ( Viracept ) Atazanavir ( Reyataz ) Clarithromycin ( Biaxin , Biaxin XL ) Itraconazole ( Sporanox ) Ketoconazole ( Nizoral ) Nefazodone ( Serzone ) Saquinavir ( Fortovase , Invirase ) Telithromycin ( Ketek ) Moderate inhibitor CYP3A4 Erythromycin ( Erythrocin , E.E.S. , EryTab , Eryc , EryPed , PCE ) Fluconazole ( Diflucan ) Grapefruit juice Verapamil ( Calan , Calan SR , CoveraHS , Isoptin SR , Verelan ) Verelan PM Diltiazem ( Cardizem , Cardizem CD , Cardizem LA , Cardizem SR , Cartia XT , Dilacor XR , Diltia XT , Taztia XT , Tiazac )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>